Vanda Pharmaceuticals | VNDA

Peers Price Chg Day Year Date
Takeda 4,528.00 -122.00 -2.62% 6.12% Sep/09
Acadia Pharmaceuticals 25.38 0.12 0.48% 60.94% Sep/08
Agios Pharmaceuticals 36.41 0.40 1.11% -17.12% Sep/08
Alnylam Pharmaceuticals 455.03 3.03 0.67% 79.74% Sep/08
Arrowhead Research 27.17 -1.91 -6.57% 24.86% Sep/08
AstraZeneca 11,970.00 -120.00 -0.99% -5.84% Sep/08
Bristol-Myers Squibb 46.72 -0.42 -0.89% -3.69% Sep/08
Halozyme Therapeutics 75.85 0.92 1.23% 28.04% Sep/08
Insmed 146.65 1.55 1.07% 104.19% Sep/08
J&J 178.18 -0.25 -0.14% 6.93% Sep/08
Ligand Pharmaceuticals 165.86 -0.89 -0.53% 61.37% Sep/08
Eli Lilly 738.59 11.38 1.56% -18.68% Sep/08
Merck 84.10 -0.61 -0.72% -27.08% Sep/08
Moderna 24.85 -0.29 -1.15% -67.58% Sep/08
Novartis 128.64 0.16 0.12% 10.21% Sep/08
Pfizer 24.56 -0.32 -1.29% -16.46% Sep/08
PTC Therapeutics 56.95 -0.31 -0.54% 81.25% Sep/08
Ultragenyx Pharmaceutical 31.53 -0.29 -0.91% -43.49% Sep/08
Sanofi 79.13 -0.37 -0.47% -25.18% Sep/08
Teva Pharmaceutical Industries 6,320.00 -42.00 -0.66% -6.37% Sep/08
Veracyte 32.46 0.03 0.09% 11.62% Sep/08

Indexes Price Day Year Date
USND 21799 98.31 0.45% 29.10% Sep/08
US2000 2396 5.00 0.21% 14.22% Sep/08

Vanda Pharmaceuticals traded at $4.38 this Tuesday April 9th, decreasing $0.14 or 2.99 percent since the previous trading session. Looking back, over the last four weeks, Vanda Pharmaceuticals lost 9.24 percent. Over the last 12 months, its price fell by 35.09 percent. Looking ahead, we forecast Vanda Pharmaceuticals to be priced at 4.34 by the end of this quarter and at 4.23 in one year, according to Trading Economics global macro models projections and analysts expectations.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, HETLIOZ (tasimelteon) for the treatment of jet lag disorder, pediatric non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD), and Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies. VSJ-110, is for the treatment of dry eye and ocular inflammation. BPO-27, is for the treatment of secretory diarrhea disorders, including cholera. Its other product includes VQW-765.